Netflix Reports Q4 Results, Q1 Guidance Misses Estimates
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 21 2026
0mins
Source: Benzinga
- Earnings Performance: Netflix's Q4 earnings report revealed revenue of $12.16 billion, exceeding expectations, yet its Q1 guidance of $12.16 billion fell short of the $12.19 billion consensus, causing shares to drop 5.7% to $82.32 in pre-market trading.
- Earnings Per Share Outlook: The company anticipates Q1 earnings per share of 76 cents, below the consensus estimate of 81 cents, indicating pressure on user growth and profitability, which may undermine investor confidence.
- Other Stock Movements: Erasca Inc announced a proposed $150 million public offering, leading to a 6.2% decline in its pre-market share price to $9.20, highlighting market sensitivity to new stock issuances.
- Market Reaction: Kraft Heinz Co shares fell 5.3% to $22.51 as Berkshire Hathaway filed to sell up to 325 million shares, intensifying market concerns regarding its future performance.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ERAS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ERAS
Wall Street analysts forecast ERAS stock price to fall
8 Analyst Rating
6 Buy
1 Hold
1 Sell
Moderate Buy
Current: 13.980
Low
2.00
Averages
5.50
High
11.00
Current: 13.980
Low
2.00
Averages
5.50
High
11.00
About ERAS
Erasca, Inc. is a clinical-stage precision oncology company. The Company is focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The Company has assembled RAS/MAPK pathway-focused pipeline in the industry, consisting of modality-agnostic programs aligned with its three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes one clinical-stage program (a pan-RAF inhibitor), two IND-enabling stage programs (a pan-RAS molecular glue and a pan-KRAS inhibitor), and an additional discovery-stage program (an EGFR D2/D3 biparatopic antibody). Its lead product candidate is naporafenib, the Company initiated its SEACRAFT-2 pivotal Phase III trial for patients with NRAS-mutated (NRASm) melanoma.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Erasca Faces Class Action Lawsuit; Investors Encouraged to Join
- Class Action Initiated: Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against Erasca, Inc., aiming to recover damages for investors who purchased its securities between January 14, 2025, and April 26, 2026, indicating strong investor response to potential violations by the company.
- Allegations Detailed: The complaint alleges that Erasca made false and misleading statements during the class period and failed to disclose that ERAS-0015's preclinical data was based on improper comparisons, potentially risking patent and trade secret protections, which could undermine investor confidence.
- Investor Actions Required: Affected investors must apply to be lead plaintiffs by August 10, 2026, highlighting the firm's commitment to investor rights and the potential reputational impact on the company stemming from legal proceedings.
- Law Firm Credentials: Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm specializing in investor rights, having recovered hundreds of millions for investors, underscoring its expertise and successful track record in securities fraud class actions.
See More
Notice of Class Action Lawsuit for Erasca, Inc. Shareholders
- Class Action Notice: The Gross Law Firm has issued a notice to shareholders of Erasca, Inc. (NASDAQ: ERAS), encouraging those who purchased shares between January 14, 2025, and April 26, 2026, to contact the firm regarding potential lead plaintiff appointment for recovery participation.
- Allegations Overview: The complaint alleges that during the class period, Erasca's management made materially false and misleading statements, failing to disclose that ERAS-0015's preclinical data was based on improper comparisons, which posed risks of violating patent and trade secret protections, thereby impacting the company's reputation and stock price.
- Critical Deadline: Shareholders must register by August 10, 2026, to participate in the class action, as missing this deadline will forfeit their opportunity to seek lead plaintiff status, highlighting the urgency and complexity of the legal process involved.
- No Cost Participation: Once registered, shareholders will be enrolled in a portfolio monitoring software to receive real-time updates on the case's progress, with no costs or obligations to participate, thus lowering the barriers for shareholder involvement.
See More
Erasca Faces Securities Class Action After 48% Stock Plunge
- Stock Plunge: Erasca's shares plummeted by $9.25 (-48%) due to patent infringement allegations, resulting in a loss of over $2.8 billion in market capitalization, indicating severe market concerns regarding the safety and intellectual property of its products.
- Legal Action: Hagens Berman is investigating whether Erasca intentionally misled investors during the class period from January 14, 2025, to April 26, 2026, potentially impacting a significant number of shareholders' rights.
- Improper Comparison Allegations: The lawsuit alleges that Erasca improperly compared its product to Revolution Medicines' competing therapy, which could lead to intellectual property disputes, thereby affecting its market reputation and future growth prospects.
- Patient Adverse Event: Following the disclosure of a patient's death one month after receiving ERAS-0015 treatment, the market reacted sharply, intensifying investor concerns about the safety profile of its product.
See More
Erasca Inc. Class Action Lawsuit Reminder
- Class Action Notice: Rosen Law Firm reminds investors who purchased Erasca common stock between January 14, 2025, and April 26, 2026, to apply as lead plaintiffs by August 10, 2026, to participate in the class action, as those who do not will not be represented.
- Lawsuit Background: Erasca, along with its CEO and CFO, is accused of violating federal securities laws by making false and misleading statements about its lead oncology drug candidate ERAS-0015 during the class period, resulting in investor losses when the truth emerged.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, being ranked number one for securities class action settlements in 2017, showcasing its expertise in this field.
- Investor Guidance: Investors are advised to carefully select legal counsel, with Rosen Law Firm recommending choosing qualified attorneys with a successful track record in leadership roles to ensure optimal representation in the class action.
See More
Investors Alert: Class Action Lawsuits Against ADMA, ERAS, NNOX
- ADMA Class Action: The class action lawsuit against ADMA Biologics, Inc. alleges that the company made materially false or misleading statements between August 9, 2024, and March 25, 2026, leading to investor losses, with a deadline of August 10, 2026, for investors to apply as lead plaintiffs to protect their rights.
- ERAS Legal Action: Similarly, the class action lawsuit against Erasca, Inc. claims that the company failed to disclose material facts from January 14, 2025, to April 26, 2026, and investors who purchased shares during this period and suffered losses are encouraged to contact legal counsel before the August 10, 2026 deadline.
- NNOX Lawsuit Details: The class action against Nano-X Imaging Ltd. alleges that the company made false statements regarding operational efficiency and cash burn from March 31, 2025, to April 17, 2026, with affected investors needing to apply as lead plaintiffs by August 11, 2026.
- Law Firm Background: Holzer & Holzer, LLC, a top-rated securities litigation firm, has been dedicated to representing shareholders since 2000, recovering hundreds of millions for investors affected by fraud, emphasizing its commitment to vigorous legal representation.
See More
Erasca Faces Securities Class Action After Patent Infringement Claims
- Stock Price Plunge: Erasca's stock plummeted by $9.25 (-48%) following accusations of patent infringement from Revolution Medicines, resulting in a market capitalization loss exceeding $2.8 billion, indicating severe market concerns regarding the safety and intellectual property of its products.
- Lawsuit Initiation: Hagens Berman has filed a securities class action against Erasca, alleging that the company misled investors between January 14, 2025, and April 26, 2026, potentially exposing investors to significant losses and highlighting the company's legal compliance risks.
- Improper Comparison Allegations: The lawsuit claims that Erasca improperly compared its ERAS-0015 to RevMed's RMC-6236, which could expose the company to intellectual property disputes, further impacting its position in the highly competitive cancer treatment market.
- Patient Adverse Event: Following the disclosure of a patient's death one month after receiving ERAS-0015, the market reacted sharply, underscoring potential safety issues that could threaten the company's future growth prospects.
See More
Erasca Faces Class Action Lawsuit; Investors Encouraged to Join
- Class Action Initiated: Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against Erasca, Inc., aiming to recover damages for investors who purchased its securities between January 14, 2025, and April 26, 2026, indicating strong investor response to potential violations by the company.
- Allegations Detailed: The complaint alleges that Erasca made false and misleading statements during the class period and failed to disclose that ERAS-0015's preclinical data was based on improper comparisons, potentially risking patent and trade secret protections, which could undermine investor confidence.
- Investor Actions Required: Affected investors must apply to be lead plaintiffs by August 10, 2026, highlighting the firm's commitment to investor rights and the potential reputational impact on the company stemming from legal proceedings.
- Law Firm Credentials: Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm specializing in investor rights, having recovered hundreds of millions for investors, underscoring its expertise and successful track record in securities fraud class actions.
See More
Notice of Class Action Lawsuit for Erasca, Inc. Shareholders
- Class Action Notice: The Gross Law Firm has issued a notice to shareholders of Erasca, Inc. (NASDAQ: ERAS), encouraging those who purchased shares between January 14, 2025, and April 26, 2026, to contact the firm regarding potential lead plaintiff appointment for recovery participation.
- Allegations Overview: The complaint alleges that during the class period, Erasca's management made materially false and misleading statements, failing to disclose that ERAS-0015's preclinical data was based on improper comparisons, which posed risks of violating patent and trade secret protections, thereby impacting the company's reputation and stock price.
- Critical Deadline: Shareholders must register by August 10, 2026, to participate in the class action, as missing this deadline will forfeit their opportunity to seek lead plaintiff status, highlighting the urgency and complexity of the legal process involved.
- No Cost Participation: Once registered, shareholders will be enrolled in a portfolio monitoring software to receive real-time updates on the case's progress, with no costs or obligations to participate, thus lowering the barriers for shareholder involvement.
See More
Erasca Faces Securities Class Action After 48% Stock Plunge
- Stock Plunge: Erasca's shares plummeted by $9.25 (-48%) due to patent infringement allegations, resulting in a loss of over $2.8 billion in market capitalization, indicating severe market concerns regarding the safety and intellectual property of its products.
- Legal Action: Hagens Berman is investigating whether Erasca intentionally misled investors during the class period from January 14, 2025, to April 26, 2026, potentially impacting a significant number of shareholders' rights.
- Improper Comparison Allegations: The lawsuit alleges that Erasca improperly compared its product to Revolution Medicines' competing therapy, which could lead to intellectual property disputes, thereby affecting its market reputation and future growth prospects.
- Patient Adverse Event: Following the disclosure of a patient's death one month after receiving ERAS-0015 treatment, the market reacted sharply, intensifying investor concerns about the safety profile of its product.
See More
Erasca Inc. Class Action Lawsuit Reminder
- Class Action Notice: Rosen Law Firm reminds investors who purchased Erasca common stock between January 14, 2025, and April 26, 2026, to apply as lead plaintiffs by August 10, 2026, to participate in the class action, as those who do not will not be represented.
- Lawsuit Background: Erasca, along with its CEO and CFO, is accused of violating federal securities laws by making false and misleading statements about its lead oncology drug candidate ERAS-0015 during the class period, resulting in investor losses when the truth emerged.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, being ranked number one for securities class action settlements in 2017, showcasing its expertise in this field.
- Investor Guidance: Investors are advised to carefully select legal counsel, with Rosen Law Firm recommending choosing qualified attorneys with a successful track record in leadership roles to ensure optimal representation in the class action.
See More
Investors Alert: Class Action Lawsuits Against ADMA, ERAS, NNOX
- ADMA Class Action: The class action lawsuit against ADMA Biologics, Inc. alleges that the company made materially false or misleading statements between August 9, 2024, and March 25, 2026, leading to investor losses, with a deadline of August 10, 2026, for investors to apply as lead plaintiffs to protect their rights.
- ERAS Legal Action: Similarly, the class action lawsuit against Erasca, Inc. claims that the company failed to disclose material facts from January 14, 2025, to April 26, 2026, and investors who purchased shares during this period and suffered losses are encouraged to contact legal counsel before the August 10, 2026 deadline.
- NNOX Lawsuit Details: The class action against Nano-X Imaging Ltd. alleges that the company made false statements regarding operational efficiency and cash burn from March 31, 2025, to April 17, 2026, with affected investors needing to apply as lead plaintiffs by August 11, 2026.
- Law Firm Background: Holzer & Holzer, LLC, a top-rated securities litigation firm, has been dedicated to representing shareholders since 2000, recovering hundreds of millions for investors affected by fraud, emphasizing its commitment to vigorous legal representation.
See More
Erasca Faces Securities Class Action After Patent Infringement Claims
- Stock Price Plunge: Erasca's stock plummeted by $9.25 (-48%) following accusations of patent infringement from Revolution Medicines, resulting in a market capitalization loss exceeding $2.8 billion, indicating severe market concerns regarding the safety and intellectual property of its products.
- Lawsuit Initiation: Hagens Berman has filed a securities class action against Erasca, alleging that the company misled investors between January 14, 2025, and April 26, 2026, potentially exposing investors to significant losses and highlighting the company's legal compliance risks.
- Improper Comparison Allegations: The lawsuit claims that Erasca improperly compared its ERAS-0015 to RevMed's RMC-6236, which could expose the company to intellectual property disputes, further impacting its position in the highly competitive cancer treatment market.
- Patient Adverse Event: Following the disclosure of a patient's death one month after receiving ERAS-0015, the market reacted sharply, underscoring potential safety issues that could threaten the company's future growth prospects.
See More
